ASH Exclusive Interview | Professor Junmin Li: Addition of Homoharringtonine Improves Induction Therapy Efficacy in Low to Intermediate-Risk AML Patients with Chemotherapy Insensitivity
Acute myeloid leukemia (AML) is a highly heterogeneous group with varying sensitivities to chemotherapy. The "7+3" regimen has been the standard induction chemotherapy for AML for 50 years. In the era of precision medicine, optimizing induction therapy for AML is a crucial issue. At the recent 65th American Society of Hematology (ASH) Annual Meeting, Professor Junmin Li's team from the Hematology Department of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, presented the initial results of the RJ-AML2016 study. This multicenter, randomized, Phase III trial investigated the efficacy of adding Homoharringtonine (HHT) to optimize the idarubicin and cytarabine induction regimen based on Day 5 Peripheral Blast Clearance Rate (D5-PBCR) in newly diagnosed young AML patients. "Hematology Frontier" had the privilege of interviewing Professor Li on the study's key findings and the team's next research plans.